For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,132 | 341* | 3,165 | 3,150 |
| Marketing expenses | - | - | 120 | 182 |
| General and administrative | 2,071 | 4,832* | 1,024 | 1,464 |
| Total operating expenses | 4,203 | 5,172 | 4,309 | 4,796 |
| Loss from operations | -4,203 | -5,172* | -4,309 | -4,796 |
| Change in fair value of derivative liabilities | 1 | -686* | - | 107 |
| Other (income) expense, net | -132 | -34* | 136 | -96 |
| Finance expense, net | - | -103* | 2 | 29 |
| Total other (income) expense | -131 | -824* | - | - |
| Net loss | -4,334 | -5,997* | -4,171 | -4,756 |
| Foreign currency translation adjustment | 3 | -6* | 8 | 29 |
| Comprehensive loss for the period | -4,331 | -6,004 | -4,163 | -4,727 |
| Basic EPS | 2.65 | -9.667 | 4.64 | 9.62 |
| Diluted EPS | 2.65 | -9.667 | 4.64 | 9.62 |
| Basic Average Shares | 1,638,128 | 621,094* | 899,410 | 494,504 |
| Diluted Average Shares | 1,638,128 | 621,094* | 899,410 | 494,504 |
Glucotrack, Inc. (GCTK)
Glucotrack, Inc. (GCTK)